Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”

dc.creator	Tsivgoulis G., Palaiodimou L., Katsanos A.H., Voumvourakis K., Hadjigeorgiou G.M., Heliopoulos I., Karapanayiotides T., Papathanasopoulos P., Kilidireas C., Grigoriadis N.	en
dc.date.accessioned	2023-01-31T10:16:50Z
dc.date.available	2023-01-31T10:16:50Z
dc.date.issued	2019
dc.identifier	10.1007/s40263-019-00615-5
dc.identifier.issn	11727047
dc.identifier.uri	http://hdl.handle.net/11615/80069
dc.description.abstract	[No abstract available]	en
dc.language.iso	en	en
dc.source	CNS Drugs	en
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062606409&doi=10.1007%2fs40263-019-00615-5&partnerID=40&md5=1338d50119f8ca3ab5c9cf42a6efefcd
dc.subject	cladribine	en
dc.subject	fingolimod	en
dc.subject	fumaric acid dimethyl ester	en
dc.subject	teriflunomide	en
dc.subject	crotonic acid derivative	en
dc.subject	fingolimod	en
dc.subject	disease activity	en
dc.subject	drug safety	en
dc.subject	human	en
dc.subject	Letter	en
dc.subject	mouth disease	en
dc.subject	multiple sclerosis	en
dc.subject	patient risk	en
dc.subject	priority journal	en
dc.subject	multiple sclerosis	en
dc.subject	Crotonates	en
dc.subject	Fingolimod Hydrochloride	en
dc.subject	Humans	en
dc.subject	Multiple Sclerosis	en
dc.subject	Springer International Publishing	en
dc.title	Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”	en
dc.type	other	en

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.